Zoetis Inc.
General ticker "ZTS" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $57.5B (TTM average)
Zoetis Inc. does not follow the US Stock Market performance with the rate: -32.4%.
Estimated limits based on current volatility of 1.8%: low 75.50$, high 78.29$
Factors to consider:
- Earnings expected soon, date: 2026-08-06 bmo
- Company included in S&P500 list
- Company pays dividends (irregularly): last record date 2026-04-20, amount 0.53$ (Y0.69%)
- Total employees count: 14500 (+5.1%) as of 2025
- US accounted for 54.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, R&D failure, Patent expiration, Regulatory and compliance, Manufacturing disruptions
- Current price 22.3% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [99.44$, 151.21$]
- 2026-12-31 to 2027-12-31 estimated range: [105.36$, 157.19$]
Financial Metrics affecting the ZTS estimates:
- Negative: with PPE of 19.5 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 36.20 > 18.65
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.74 > 6.08
- Positive: 19.10 < Shareholder equity ratio, % of 21.54 <= 42.34
- Positive: Inventory ratio change, % of 0.37 <= 0.80
- Positive: Industry inventory ratio change (median), % of -0.44 <= -0.15
- Positive: 0.30 < Operating cash flow per share per price, % of 5.23
- Negative: 0.01 < Interest expense per share per price, % of 0.44
- Negative: negative Industry operating cash flow (median)
Short-term ZTS quotes
Long-term ZTS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $8,464.00MM | $9,050.00MM | $9,281.00MM |
| Operating Expenses | $5,528.00MM | $5,917.00MM | $5,921.00MM |
| Operating Income | $2,936.00MM | $3,133.00MM | $3,360.00MM |
| Interest Expense | $258.00MM | $242.00MM | $243.00MM |
| R&D Expense | $614.00MM | $686.00MM | $698.00MM |
| Income(Loss) | $2,936.00MM | $3,133.00MM | $3,360.00MM |
| Taxes | $596.00MM | $637.00MM | $687.00MM |
| Net Income(Loss)* | $2,344.00MM | $2,486.00MM | $2,673.00MM |
| Stockholders Equity | $4,997.00MM | $4,770.00MM | $3,331.00MM |
| Inventory | $2,564.00MM | $2,306.00MM | $2,430.00MM |
| Assets | $14,286.00MM | $14,237.00MM | $15,467.00MM |
| Operating Cash Flow | $2,353.00MM | $2,953.00MM | $2,904.00MM |
| Capital expenditure | $732.00MM | $655.00MM | $621.00MM |
| Investing Cash Flow | $-777.00MM | $-315.00MM | $-748.00MM |
| Financing Cash Flow | $-3,109.00MM | $-2,660.00MM | $-1,870.00MM |
| Earnings Per Share** | $5.08 | $5.47 | $6.03 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.